- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor "What This Means" Segment About its Proprietary T-Cell Engager Program | 1 | GlobeNewswire (USA) | ||
| 18.09. | HCW Biologics Inc.: HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing | 1 | GlobeNewswire (USA) | ||
| 16.09. | HCW Biologics Inc.: HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development | 230 | GlobeNewswire (Europe) | Lead product candidate will be advanced to late IND-enabling studies to prepare for clinical trials for evaluation in the treatment of solid tumors Discovery of unique combination of cytokines in... ► Artikel lesen | |
| 12.09. | Why Is HCW Biologics Stock Surging 102% Overnight? | 3 | Benzinga.com | ||
| 09.09. | HCW Biologics Inc.: HCW Biologics Reports Positive Results from Non-Human Primate Study for Its Proprietary Second-Generation T-Cell Engager Program | 234 | GlobeNewswire (Europe) | HCW Biologics conducted investigative study to show safe dose levels of its lead drug candidate in non-human primates that were well tolerated at a level significantly higher than the identified efficacious... ► Artikel lesen | |
| HCW BIOLOGICS Aktie jetzt für 0€ handeln | |||||
| 05.09. | HCW Biologics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.08. | HCW Biologics' Shares Surge After Unveiling Next-Gen Cancer Immunotherapy Platform | 1 | Benzinga.com | ||
| 25.08. | HCW Biologics meldet vielversprechende Ergebnisse für neue Krebs-Immuntherapie | 15 | Investing.com Deutsch | ||
| 25.08. | HCW Biologics stock soars on novel cancer immunotherapy breakthrough | 1 | Investing.com | ||
| 25.08. | HCW Biologics reports promising results for new cancer immunotherapy | 1 | Investing.com | ||
| 25.08. | HCW Biologics Inc.: HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market | 3 | GlobeNewswire (USA) | ||
| 19.08. | HCW Biologics erhält Delisting-Mitteilung von der NASDAQ und plant Anhörung | 3 | Investing.com Deutsch | ||
| 19.08. | HCW Biologics GAAP EPS of -$16.16, revenue of $180.4M | 1 | Seeking Alpha | ||
| 19.08. | HCW Biologics GAAP EPS of -$16.16 | 1 | Seeking Alpha | ||
| 18.08. | HCW Biologics Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 18.08. | HCW Biologics Inc.: HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results | 778 | GlobeNewswire (Europe) | MIRAMAR, Fla., Aug. 18, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing... ► Artikel lesen | |
| 15.08. | HCW Biologics Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 1 | SEC Filings | ||
| 14.08. | HCW Biologics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.07. | HCW Biologics Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 01.07. | HCW Biologics meldet vollständige Ausübung von vorfinanzierten Optionsscheinen durch Armistice Capital | 7 | Investing.com Deutsch |
1 2 3 Weiter >>
56 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | - | - | PALATIN TECHNOLOGIES INC - S-1/A, General form for registration of securities | ||
| BIOXXMED | 0,120 | 0,00 % | PTA-News: bioXXmed AG: Ergebnis der Zeichnung der Wandelschuldverschreibung | DJ PTA-News: bioXXmed AG: Ergebnis der Zeichnung der Wandelschuldverschreibung
Unternehmensmitteilung für den Kapitalmarkt
bioXXmed AG: Ergebnis der Zeichnung der Wandelschuldverschreibung... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer | SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing... ► Artikel lesen | |
| OCUGEN | 1,560 | +4,17 % | Ocugen plant drei Zulassungsanträge für Gentherapien gegen Erblindung bis 2028 | ||
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem Corp.: Sirona Biochem Update to Shareholders on Financial Status and Operations | VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") wishes to provide shareholders with a critical update on the company's financial... ► Artikel lesen | |
| BIO-GATE | 0,900 | -3,23 % | EQS-News: Bio-Gate AG: Bio-Gate veröffentlicht Halbjahreszahlen und bestätigt den Ausblick für 2025 | EQS-News: Bio-Gate AG
/ Schlagwort(e): Halbjahresbericht/Halbjahresergebnis
Bio-Gate veröffentlicht Halbjahreszahlen und bestätigt den Ausblick für 2025
30.09.2025 / 15:07... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,479 | +3,23 % | Defence Therapeutics Inc.: Defence Therapeutics Appoints Dr. Mark Lambermon as Head of Quality and Operations | Montreal, Quebec--(Newsfile Corp. - October 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug... ► Artikel lesen | |
| VAXART | 0,277 | -1,00 % | Vaxart, Inc.: Vaxart Announces Withdrawal of Reverse Stock Split Proposal | SOUTH SAN FRANCISCO, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 1,410 | +4,44 % | Burcon NutraScience Corporation: Burcon Announces New Board Members and Results of Shareholder Meeting | Vancouver, British Columbia--(Newsfile Corp. - September 17, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) (the "Burcon" or the "Company"), a global technology leader in plant-based... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 5,820 | 0,00 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update | Intend to Pursue an NDA Submission to the U.S. FDA under Accelerated Approval Pathway for Iopofosine I 131 for the Treatment of Waldenstrom Macroglobulinemia (WM) Subject to Sufficient Funding and... ► Artikel lesen | |
| AFFIMED | 0,972 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 28.05.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.05.2025ISIN NameBMG3728V1090 GAN... ► Artikel lesen | |
| AIM IMMUNOTECH | 0,073 | -100,00 % | AIM ImmunoTech Inc.: AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen (Rintatolimod) with Checkpoint Inhibitors | Patent supports AIM's strategy to expand international market protection, providing opportunities for licensing, collaborations, and long-term revenue growth Japan is the third-largest pharmaceutical... ► Artikel lesen | |
| IMMUNIC | 0,817 | -0,85 % | EQS-News: Immunic AG: Immunic to Participate in Scientific and Investor Conferences in October | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Participate in Scientific and Investor Conferences in October
01.10.2025 / 12:30 CET/CEST
The issuer is solely... ► Artikel lesen | |
| T2 BIOSYSTEMS | 0,250 | 0,00 % | NSE/A - T2 Biosystems, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| CEL-SCI | 8,550 | +1,79 % | XFRA LSR: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen |
Das Unternehmen HCW BIOLOGICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 3,700 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HCW BIOLOGICS INC finden Sie auf Wallstreet Online.